Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,496 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 4 Interventional

The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric

NCT03054831
View directory record Official record
Conditions
Liquid Oxycodone
Interventions
liquid oxycodone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 8 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

Grand Valley State University (GVSU) Skills on Wheels

NCT05339932
View directory record Official record
Conditions
Spina Bifida, Cerebral Palsy, Genetic Disease, Spinal Cord Injuries, Gross Motor Development Delay, Motor Skills Disorders
Interventions
Manual Wheelchair Skills Training
Other
Lead sponsor
Grand Valley State University
Other
Eligibility
5 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334
View directory record Official record
Conditions
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions
Osimertinib, Ramucirumab
Drug
Lead sponsor
Xiuning Le
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption

NCT06146608
View directory record Official record
Conditions
Anemia, Iron Deficiency, Iron Overload
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions
LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Early Phase 1 Interventional

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874
View directory record Official record
Conditions
Breast Cancer, Early-Onset
Interventions
Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

Sling vs No Sling After Reverse Total Shoulder Arthroplasty

NCT06092996
View directory record Official record
Conditions
Shoulder Disease, Rotator Cuff Tear Arthropathy, Shoulder Osteoarthritis
Interventions
Time of Sling Use
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 1 Interventional

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

NCT01586403
View directory record Official record
Conditions
Melanoma
Interventions
Dose 1, Dose 2, Dose 3, Dose 4
Biological
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair

NCT06710795
View directory record Official record
Conditions
Ventral Hernia
Interventions
MaxTack™ Motorized Fixation Device
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Weston, Florida • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03314181
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Venetoclax, Bortezomib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
14
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 3 Interventional

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Trial of Pistachio Consumption in Older Adults

NCT06992544
View directory record Official record
Conditions
Cognition, Cardiometabolic Risk Factors, Life Satisfaction
Interventions
Pistachio-enriched diet, Usual diet
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

Conservative Management for PAS Pilot

NCT05139498
View directory record Official record
Conditions
Placenta Accreta
Interventions
Conservative management for placenta accreta spectrum (PAS), Cesarean hysterectomy for placenta accreta spectrum (PAS)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

NCT01629498
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Questionnaire Administration
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

Cross-disciplinary HIV Integrated Mental Health Support Intervention

NCT04833829
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV Infections
Interventions
CHIMES Intervention, Standard of Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT06845202
View directory record Official record
Conditions
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

NCT05681039
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Tiragolumab, Atezolizumab, Standard of Care, Questionnaires, Cisplatin, Carboplatin
Drug · Behavioral · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting No phase listed Observational

Evaluating the InPen in Pediatric Type 1 Diabetes

NCT05515939
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen Insulin Pen
Device
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting No phase listed Observational

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

NCT03350828
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
4 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b-njft (P1101)
Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Not applicable Interventional

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909
View directory record Official record
Conditions
Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Active, not recruiting Phase 2 Interventional Results available

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

NCT04090528
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
Interventions
pTVG-HP, pTVG-AR, Pembrolizumab
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 7:10 AM EST